American Well Corporation
American Well Corporation, an enterprise platform and software company, delivers digitally enabling hybrid care in the United States and internationally. The company offers Amwell Platform, a cloud-based enablement platform, digitally enables a scalable healthcare experience across all care settings; Amwell Carepoint,…
1D
-5.7%
1W
-8.0%
1M
-12.4%
6M
+90.8%
YTD
+137.9%
1Y
+105.6%
2Y
+13.8%
5Y
-93.1%
10Y
–
Next earnings date
03/11/2026 (in 17 days)
Volatility around earnings
~60% stronger price swings than usual
PRICE TARGET LOW
US$11.00
CONSENSUS
US$13.00
MEDIAN
US$12.50
PRICE TARGET HIGH
US$16.00
0
STRONG BUY
5
BUY
10
HOLD
0
SELL
0
STRONG SELL
15
TOTAL · Hold
As of: 13/08/2026
P/E
-2.45
P/B
0.88
EV/EBITDA
-0.13
RETURN ON EQUITY
-4.5%
NET MARGIN
-19.1%
DEBT/EQUITY
0.01
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
FREE FLOAT
80.9%
FLOAT SHARES
13,766,423
AVG. DAILY VOLUME (30D)
98,711
Zamansky Dmitry
Gotlib Phyllis
McNeice Paul Francis
HIRSCHHORN MARK
McNeice Paul Francis
American Well Corporation is a company in the Healthcare sector, Medical - Healthcare Information Services industry, headquartered in United States.
The CEO is Ido Schoenberg, the company employs around 562 people.
The IPO was on 17/09/2020; the stock trades on NYSE under the ticker AMWL.
15 analysts rate the stock, the consensus is Hold (as of 13/08/2026).
The average price target is US$13.00, ranging from US$11.00 to US$16.00, with a median of US$12.50.
This is an external assessment, not a statement by Market Jury.
The next earnings date is 03/11/2026.
Around past earnings, price swings were roughly 60% stronger than usual.
No, American Well currently does not pay a dividend.
Comparable stocks include Hinge Health, HealthEquity, Heartflow, Omada Health, Teladoc Health, Evolent Health, SOPHiA GENETICS and Optima Health.
Clicking "Analyze stock" lets five strategies assess American Well against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.